The post-finasteride syndrome: possible etiological mechanisms and symptoms.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic hypotheses without new empirical data or systematic review methodology
PubMed 37697052 · doi:10.1038/s41443-023-00759-5
What was done
This narrative review summarizes the clinical presentation and potential biological mechanisms underlying post-finasteride syndrome in patients treated with the 5α-reductase inhibitors finasteride and dutasteride for alopecia or benign prostatic hyperplasia.
What was found
The abstract reports no numerical data, effect sizes, or risk estimates. It qualitatively describes that a small subgroup of patients experiences persistent sexual, neurological, psychiatric, endocrinological, metabolic, and ophthalmological dysfunctions after stopping 5α-reductase inhibitors. Mechanistically, lipophilic 5α-reductase inhibitors cross the blood-brain barrier, which may inhibit central neurosteroid synthesis and impair neurogenesis beyond peripheral dihydrotestosterone reduction.
Why it matters
The review outlines plausible neurobiological mechanisms behind post-finasteride syndrome, emphasizing that prescribers should carefully weigh persistent multi-system risks against the clinical benefits of 5α-reductase inhibitors.
Limits
The abstract contains no primary experimental or clinical trial data, no sample size, and no systematic search protocol. Proposed mechanisms are largely theoretical, and the true incidence, risk factors, and causal links remain unquantified.
Cited by
- supports Some patients experience persistent sexual dysfunction even after discontinuing finasteride treatment for hair loss.